Johnson & Johnson Showcases TECNIS PureSee IOL Data
Jacksonville, Florida | April 10, 2026 Johnson & Johnson has presented new clinical data for its TECNIS PureSee⢠intraocular...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
Jacksonville, Florida | April 10, 2026 Johnson & Johnson has presented new clinical data for its TECNIS PureSee⢠intraocular...
SPRING HOUSE, Pennsylvania, USA ā March 18, 2026 In a major advancement for dermatology and systemic therapies, Johnson &...
SPRING HOUSE, Pa., March 3, 2026 Johnson & Johnson has received U.S. Food and Drug Administration (FDA) Fast Track...
